

Delineation of functional roles of parasite-specific inserts in the malarial S-adenosylmethionine decarboxylase / ornithine decarboxylase

By

**Marni Williams
25026519**

Submitted in partial fulfilment of the requirements for the degree MSc. Biochemistry in the Faculty of Natural and Agricultural Science

**Department of Biochemistry
University of Pretoria
Pretoria
South Africa**

February 2008



I declare that the thesis/dissertation, which I hereby submit for the degree MSc. Biochemistry at the University of Pretoria, is my own work and has not previously been submitted by me for a degree at this or any other tertiary institution.

SIGNATURE:

DATE:

Acknowledgements

- Prof A.I. Louw, University of Pretoria, South Africa (Promoter)
- Dr L. Birkholtz, University of Pretoria, South Africa (Co-promoter)
- Prof R.D. Walter, Dr C. Wrenger, Dr I.B. Müller, M. Eschbach, B. Bergmann, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (Collaborative research visit in 2006)
- Dr P.F.G. Sims, Manchester Interdisciplinary Biocentre, Manchester, United Kingdom (Mass spectrometric analysis)
- Dr M. Rautenbach, University of Stellenbosch, South Africa (Design of synthetic peptides)
- G.A. Wells, University of Pretoria, South Africa (Secondary structure predictions)
- National Research Foundation (Grand holder's bursary)
- Family and friends

Contents

List of Figures	IV
List of Tables	VI
List of Abbreviations	VII
Chapter 1: Literature review	1
1.1 Malaria	1
1.2 The <i>P. falciparum</i> life cycle	2
1.3 Treating malaria	3
1.3.1 Vector control	3
1.3.2 Vaccine development.....	6
1.3.3 Current antimalarials	8
1.3.3.1 Quinolines	9
1.3.3.2 Antifolates	10
1.3.3.3 Artemisinins.....	11
1.3.3.4 Antibiotics.....	13
1.3.4 Novel antimalarial targets	13
1.3.4.1 Type II fatty acid biosynthesis	13
1.3.4.2 DNA topoisomerases	14
1.3.4.3 Polyamine biosynthesis.....	14
1.4 Polyamines	15
1.4.1 Polyamine metabolism in <i>P. falciparum</i>	16
1.4.2 Polyamine transporters	18
1.4.3 Polyamine levels during malarial infection	19
1.4.4 Polyamine biosynthetic enzymes as drug targets	20
1.4.4.1 The bifunctional PfAdoMetDC/ODC protein	23
1.4.4.2 Ornithine decarboxylase	24
1.4.4.3 S-adenosylmethionine decarboxylase	25
1.4.4.4 Parasite-specific inserts	26
1.5 Research aims	29
Chapter 2: An efficient method for the deletion of parasite-specific inserts in malarial genes	30
2.1 Introduction	30
2.2 Methods	33
2.2.1 Deletion mutagenesis PCR.....	33
2.2.1.1 Cloning of genes into pASK-IBA3	33
2.2.1.2 QuickChange™ site-directed mutagenesis (QCM)	33
2.2.1.3 ExSite™ PCR-based site-directed mutagenesis	34
2.2.1.4 Overlapping primer method.....	34
2.2.1.5 Inverse PCR method.....	34
2.2.1.6 RE-mediated inverse PCR method	34
2.2.1.7 Analysis of mutagenesis products.....	35
2.2.1.8 Electroporation into DH5α cells.....	35
2.2.1.9 Plasmid isolation	36
2.2.1.10 Restriction enzyme mapping.....	37
2.2.1.11 Nucleotide sequencing.....	37
2.3 Results and Discussion.....	38
2.3.1 Analysis of mutagenesis products.....	38
2.3.2 Verification of the RE-mediated inverse PCR method	42
Chapter 3: Delineation of the roles of structural features in the PfAdoMetDC parasite-specific inserts on bifunctional activity	45
3.1 Bifunctional enzymes in <i>P. falciparum</i>	45
3.2 Parasite-specific inserts in PfAdoMetDC/ODC	46
3.3 Identification of secondary structures	47
3.3.1 Hydrophobic cluster analysis	48

3.3.2	The roles of secondary structures in protein-protein interactions and motif formation	49
3.3.2.1	α -Helices and protein-protein interactions.....	49
3.3.2.2	β -Sheets, barrels and turns.....	51
3.4	Methods.....	52
3.4.1	Delineation of structural features within the PfAdoMetDC parasite-specific inserts.....	52
3.4.2	Nucleotide deletion of the PfAdoMetDC parasite-specific inserts and mutagenesis of delineated areas	55
3.4.2.1	Cloning of <i>PfAdoMetDC/ODC</i> into pASK-IBA3	55
3.4.2.2	Mutagenesis PCR	55
3.4.2.3	Post-PCR manipulations.....	56
3.4.2.4	Plasmid isolation and nucleotide sequencing	57
3.4.3	Recombinant protein expression and isolation of the mutated PfAdoMetDC/ODC proteins	57
3.4.3.1	Heat shock transformation	57
3.4.3.2	Protein expression induction and expression.....	58
3.4.3.3	Isolation of the <i>Strep</i> -tagged recombinant proteins	59
3.4.3.4	Protein concentration determination	59
3.4.3.5	SDS-PAGE analysis.....	60
3.4.3.6	MS analysis of the mutant PfAdoMetDC/ODC proteins	60
3.4.3.7	AdoMetDC and ODC activity assays	61
3.4.3.8	Statistical analysis.....	62
3.5	Results and Discussion.....	62
3.5.1	The identification of structural features within the PfAdoMetDC inserts	62
3.5.2	Deletion of the parasite-specific inserts in PfAdoMetDC.....	64
3.5.3	Mutagenesis of delineated areas within the PfAdoMetDC parasite-specific inserts.....	66
3.5.4	Influence of the PfAdoMetDC inserts on bifunctional activity.....	67
3.5.4.1	Isolation of the mutant PfAdoMetDC/ODC proteins	67
3.5.4.2	MS analysis of the PfAdoMetDC insert-deleted proteins	71
3.5.4.3	Activity assays of the PfAdoMetDC insert-deleted proteins	73
3.5.5	The roles of secondary structures within the PfAdoMetDC inserts on bifunctional activity	77
3.5.5.1	Recombinant protein expression of the newly created constructs	77
3.5.5.2	Activity assays of the secondary structure-mutated proteins	79
Chapter 4: Investigations of the conserved O1 parasite-specific insert.....		83
4.1	Introduction	83
4.2	Peptides as therapeutic inhibitors of protein-protein interactions	84
4.2.1	Important criteria for the design of interface peptides.....	86
4.3	Methods	88
4.3.1	Mutagenesis of areas within the O1 insert of PfODC.....	88
4.3.1.1	Cloning of monofunctional <i>PfODC</i> into pASK-IBA3	88
4.3.1.2	Site-directed mutagenesis.....	88
4.3.1.3	Post-PCR analysis	89
4.3.1.4	Plasmid isolation and restriction enzyme screening	90
4.3.1.5	Nucleotide sequencing.....	90
4.3.1.6	Protein expression and isolation	90
4.3.2	Size-exclusion FPLC for the determination of protein sizes.....	91
4.3.2.1	Calibration of column with protein standards	91
4.3.2.2	Separation of proteins by size-exclusion FPLC	92
4.3.2.3	Western immunodetection of collected protein fractions.....	92
4.3.3	Synthetic peptides targeting protein-protein interactions in the O1 insert.....	93
4.3.3.1	Isolation of wild type PfAdoMetDC/ODC protein.....	93
4.3.3.2	Protein:peptide incubation.....	93
4.3.3.3	Activity determination of the protein:peptide samples.....	94
4.3.3.4	Statistical analysis.....	94

4.4	Results and Discussion.....	94
4.4.1	Creation of monofunctional PfODC insert O1 mutations.....	94
4.4.2	Size-exclusion FPLC.....	99
4.4.2.1	Calibration of column with protein standards	99
4.4.2.2	Separation of the isolated recombinant proteins by SEC.....	102
4.4.2.3	Western dot blots	106
4.4.3	Synthetic peptides as inactivators of multimeric enzymes	109
4.4.3.1	Protein:peptide incubation.....	110
4.4.3.2	Activity assays of protein:peptide samples	110
	Chapter 5: Concluding discussion.....	116
	Summary	126
	References	128
	Appendices	139

List of Figures

Figure 1.1: The worldwide distribution of malaria.....	1
Figure 1.2: The <i>P. falciparum</i> merozoite showing the apical complex and other major cellular organelles and structures.....	2
Figure 1.3: The life cycle of the <i>P. falciparum</i> parasite.....	3
Figure 1.4: Kingsley Holgate and his One net, one life anti-malaria campaign supported by Nando's.	4
Figure 1.5: Annual recorded malaria cases and deaths in South Africa (1971-2004).....	5
Figure 1.6: Selected malaria vaccines targeting different antigens in specific stages of the parasite life cycle.....	7
Figure 1.7: A schematic diagram of the parasite life cycle within the human host showing the targets of different antimalarials during the developmental stages.	8
Figure 1.8: Structures of the positively charged polyamines: the divalent putrescine, trivalent spermidine and tetravalent spermine.	16
Figure 1.9: Outlines of the polyamine metabolic pathways in the mammalian cell and the <i>P. falciparum</i> parasite.	17
Figure 1.10: The polyamine biosynthesis pathway in <i>P. falciparum</i>	18
Figure 1.11: Stage-specific polyamine content of <i>P. falciparum</i> -infected erythrocytes.	20
Figure 1.12: Schematic diagram of the bifunctional <i>P. falciparum</i> AdoMetDC/ODC protein.....	23
Figure 1.13: The head-to-tail organisation of the two monofunctional <i>P. falciparum</i> ODC monomers.....	24
Figure 1.14: Diagram of the monofunctional <i>P. falciparum</i> AdoMetDC homology model showing the $\alpha\beta\beta\alpha$ structural arrangement.....	26
Figure 2.1: Overview of four currently used deletion mutagenesis PCR methods.....	32
Figure 2.2: Agarose gel electrophoresis of the PCR products obtained with the various deletion mutagenesis PCR methods.	38
Figure 2.3: Nucleotide sequencing chromatograms of the largest insert deletion products (A/O Δ A3) obtained with the overlapping primer and RE-mediated inverse PCR methods.	39
Figure 2.4: Schematic representation of the RE-mediated inverse PCR method.	41
Figure 2.5: Agarose gel electrophoresis of the PfPdxK insert-deleted PCR product after RE-mediated inverse PCR.	42
Figure 2.6: <i>EcoRI</i> restriction enzyme mapping of the wild type and insert-deleted PfPdxK plasmids obtained with the RE-mediated inverse PCR method.	43
Figure 3.1: The bifunctional <i>P. falciparum</i> AdoMetDC/ODC protein together with results of previous structure-function relationship studies.....	47
Figure 3.2: Hydrophobic cluster analysis: between sequence and structure.	54
Figure 3.3: Secondary structure prediction results of the A2 and A3 insert sequences.	63
Figure 3.4: HCA plots for the A2 and A3 parasite-specific inserts in <i>P. falciparum</i> AdoMetDC/ODC.	64
Figure 3.5: Agarose gel electrophoresis of the A/O Δ A1 and A/O Δ A2 PCR products.	65
Figure 3.6: Nucleotide sequencing chromatograms of the PfAdoMetDC/ODC insert-deleted constructs.	65
Figure 3.7: Agarose gel electrophoresis of the A/OpA2a and A/O Δ A3b PCR products.....	66
Figure 3.8: Nucleotide sequencing chromatograms of the A/OpA2a and A/O Δ A3b constructs.....	67
Figure 3.9: Protein expression levels of the wild type PfAdoMetDC/ODC and the PfAdoMetDC insert-deleted proteins.	68
Figure 3.10: SDS-PAGE analysis of the expressed wild type and the bifunctional PfAdoMetDC insert-deleted recombinant proteins.....	69
Figure 3.11: Peptides identified with MS aligned with the PfAdoMetDC/ODC sequence.	72
Figure 3.12: AdoMetDC activity assays of the wild type PfAdoMetDC/ODC and bifunctional PfAdoMetDC insert-deleted proteins.....	74
Figure 3.13: ODC activity assays of the wild type PfAdoMetDC/ODC and bifunctional PfAdoMetDC insert-deleted proteins.	74
Figure 3.14: Protein expression levels of the wild type PfAdoMetDC/ODC and A/OpA2a proteins.	77
Figure 3.15: SDS-PAGE analysis of the wild type and A/OpA2a recombinant proteins.	78
Figure 3.16: AdoMetDC activity assays of the of the wild type PfAdoMetDC/ODC and bifunctional A/OpA2a mutant proteins.....	80
Figure 3.17: ODC activity assays of the wild type PfAdoMetDC/ODC and bifunctional A/OpA2a mutant proteins.....	80
Figure 4.1: A model diagram depicting the association between Glycophorin A's α -helix and a synthetic peptide.....	86
Figure 4.2: The sites of the mobile Gly residues and the α -helix in the O1 parasite-specific insert.	95

Figure 4.3: Agarose electrophoresis gels of the monofunctional PfODC O1 insert PCR mutagenesis products.	96
Figure 4.4: Agarose gel electrophoresis of the ODCpO1a <i>Hind</i> III digested plasmids.	96
Figure 4.5: <i>Eco</i> RV restriction enzyme screening of the ODCpG1 plasmids.	97
Figure 4.6: Agarose gel electrophoresis of the ODCpG2 <i>Hind</i> III digested plasmids.	98
Figure 4.7: Nucleotide sequencing chromatograms of all three the monofunctional PfODC O1 insert mutations.	99
Figure 4.8: A schematic diagram showing the sizes of the bifunctional as well as the monofunctional multimeric proteins.	100
Figure 4.9: SEC elution profile of Dextran Blue for the determination of the void volume of the size-exclusion column.	100
Figure 4.10: Elution profile of protein standards by size-exclusion FPLC.	101
Figure 4.11: Elution profile of four selected protein standards by size-exclusion FPLC.	102
Figure 4.12: Elution profile of the bifunctional PfAdoMetDC/ODC proteins separated with size-exclusion FPLC.	103
Figure 4.13: Elution profile of monofunctional proteins separated with size-exclusion FPLC.	105
Figure 4.14: Western immunodetection of the fractions obtained from size-exclusion FPLC of the different bifunctional PfAdoMetDC/ODC proteins.	107
Figure 4.15: Western immunodetection of the fractions obtained from size-exclusion FPLC of the different monofunctional PfODC proteins.	108
Figure 4.16: AdoMetDC and ODC activity assays after a 30 min incubation of three different peptides with PfAdoMetDC/ODC at three different molar quantities of the peptides.	111
Figure 4.17: AdoMetDC and ODC activity assays after a 2 hr incubation of three different peptides with PfAdoMetDC/ODC at three different molar quantities of the peptides.	113
Figure 1A: Relative quantity band analyses of the expressed bifunctional wild type and PfAdoMetDC insert-deleted recombinant proteins.	139
Figure 1B: Relative quantity band analyses of the expressed bifunctional wild type and insert A2 α -helix disrupted recombinant proteins.	140

List of Tables

Table 1.1: Different antimalarial drug classes together with their mechanisms of action	9
Table 1.2: Mammalian ODC and AdoMetDC versus <i>P. falciparum</i> AdoMetDC/ODC	21
Table 2.1: Primers used for the various deletion mutagenesis protocols	33
Table 2.2: Deletion mutagenesis efficiency results for the different protocols used	39
Table 3.1: The mutagenic primers and their properties for the deletion of the smaller parasite-specific inserts in PfAdoMetDC	55
Table 3.2: The mutagenic primers and their properties for the disruption of the secondary structures within the PfAdoMetDC parasite-specific inserts	56
Table 3.3: The AdoMetDC and ODC radioactivity assay reactions	61
Table 3.4: Peptides identified with MS	71
Table 4.1: The mutagenic primers for the introduction of specific mutations in the O1 insert of the monofunctional <i>PfODC</i> gene	89
Table 4.2: Protein standards for the calibration of the size-exclusion chromatography column	92
Table 4.3: Calculated MW of the peaks detected with SEC for the bifunctional proteins	104
Table 4.4: Calculated MW of the peaks detected with SEC for the monofunctional proteins	105
Table 4.5: Possible peptides as interface inhibitors of PfODC dimerisation	109
Table 5.1: Summary of the effects of O1 insert mutations on protein activity and dimerisation as well as its targeting with peptide inhibitors	125
Table 1A: Relative quantities obtained after band analyses of the bifunctional wild type and PfAdoMetDC insert-deleted protein samples	140
Table 1B: Relative quantities obtained after band analyses of the bifunctional wild type and insert A2 α -helix disrupted protein samples	141

List of Abbreviations

ACC	Acetyl-CoA carboxylase
ACT	Artemisinin-based combination therapy
ADA	Adenosine deaminase
AdoDATO	S-adenosyl-1,8-diamino-3-thio-octane
AdoMet	S-adenosylmethionine
AdoMetDC	S-adenosylmethionine decarboxylase
AdoMetDC/ODC	S-adenosylmethionine decarboxylase/ornithine decarboxylase
AHT	Anhydrotetracycline
AMA-1	Apical membrane antigen 1
AMP	Adenosine 5'-monophosphate
APA	3-Aminoxy-1-aminopropane
AZ	Antizyme
bp	Base pair
BSA	Bovine serum albumin
bZIP	Basic-leucine-zipper
CCMB	Calcium-manganese based
CPM	Counts per minute
CSP	Circumsporozoite protein
DDT	bis (4-chlorophenyl)-1,1,1-trichloroethane
DFMO	α -Difluoromethylornithine
DHFR	Dihydrofolate reductase
DHFS	Dihydrofolate synthase
DHNA	Dihydroneopterin aldolase
DHPS	Dihydropteroate synthase
DHS	Deoxyhypusine synthase
DMSO	Dimethyl sulfoxide
DOHH	Deoxyhypusine hydroxylase
DNA	Deoxyribonucleic acid
dNTP	Deoxyribonucleotide 5'-triphosphate
DTT	Dithiothreitol
EDTA	Ethylenediamine tetraacetic acid
eIF5A	Eukaryotic translation initiation factor 5A
ENR	Enoyl-ACP-reductase
FMP-1	Falciparum merozoite protein 1
FP	Fowl pox
FPGS	Folypolyglutamate synthase
FPLC	Fast protein liquid chromatography
Glc6PD/6PGL	Glucose-6-phosphate dehydrogenase/6-phosphoglucolactonase
GluK	Glutamate-5-kinase
Glu-PreD	Glutamylphosphate reductase
GLURP	Glutamine-rich protein
GluS	Glutamate synthase
GMP	Guanosine 5'-monophosphate
GpA	Glycophorin A
GTP	Guanosine 5'-triphosphate
GTPCH	Guanosine 5'-triphosphate cyclohydrolase I



HABA	4-Hydroxy azobenzene-2-carboxylic acid
HBsAg	Hepatitis B surface antigen
HCA	Hydrophobic cluster analysis
HDM2	Human double minute 2
HGXPRT	Hypoxanthine-guanine-xanthine phosphoribosyl transferase
HIV/AIDS	Human immunodeficiency virus/acquired immunodeficiency syndrome
HPLC	High performance liquid chromatography
Hrs	Hours
HSP	Heat shock protein
HSS	Homospermidine synthase
IMP	Inosine 5'-monophosphate
kb	Kilobase
kDa	Kilodalton
LB	Luria Bertani
LCRs	Low-complexity regions
LSA-1	Liver stage antigen 1
4MCHA	<i>trans</i> -4-methylcyclohexylamine
MDM2	Mouse double minute 2
ME-TRAP	Multi-epitope thrombospondin-related adhesive protein
MMV	Medicines for Malaria Venture
MS	Mass spectrometry
MSP	Merozoite surface protein
MTA	5'-Methylthioadenosine
MTI	5'-Methylthioinosine
MVA	Modified vaccinia virus Ankara
MVI	Malaria Vaccine Initiative
MW	Molecular weight
NaCl	Sodium chloride
NADH	Nicotinamide adenine dinucleotide
nt	nucleotide
OAc	Acetate
OAT	Ornithine aminotransferase
ODC	Ornithine decarboxylase
pABA	<i>p</i> -aminobenzoic acid
PAGE	Polyacrylamide gel electrophoresis
PAO	Polyamine oxidase
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PCRed	1-Pyrroline-5-carboxylate reductase
PdxK	Pyridoxal kinase
PfEMP1	<i>Plasmodium falciparum</i> erythrocyte membrane protein 1
Pfs	<i>P. falciparum</i> surface antigens
PNP	Purine nucleoside phosphorylase
PLP	Pyridoxal-5'-phosphate
PMSF	Phenylmethylsulfonyl fluoride
PPPK	Hydroxymethyldihydropterin pyrophosphokinase
QCM	QuickChange™ site-directed mutagenesis



RBC	Red blood cell
RBM	Roll Back Malaria
RE	Restriction enzyme
rPfHinge-ODC	Recombinant <i>P. falciparum</i> ODC plus 144 amino acids of the hinge region
rPfODC	Recombinant <i>P. falciparum</i> ODC
RNA	Ribonucleic acid
rpm	Revolutions per minute
SA	Specific activity
SDS	Sodium dodecylsulphate
SDS-PAGE	Sodium dodecylsulphate polyacrylamide gel electrophoresis
SEC	Size-exclusion chromatography
SERCA	Sarcoplasmic-endoplasmic reticulum calcium adenosine triphosphatase
SHMT	Serine hydroxymethyltransferase
SNAP25	Synaptosome-associated protein 25
SNARE	Soluble <i>N</i> -ethylmaleimide-sensitive factor attachment protein receptors
SpdSyn	Spermidine synthase
SpmSyn	Spermine synthase
SSAT	Spermidine/spermine- <i>N</i> ¹ -acetyltransferase
TAE	Tris-acetate ethylenediamine tetraacetic acid
TEMED	N,N,N,N -Tetramethyl-Ethylenediamine
T _m	Melting temperature
TRAP	Thrombospondin-related adhesive protein
Tris-HCl	Trishydroxy (methyl-amino) methane/hydrochloric acid
TS	Thymidylate synthase
U	Units
UNICEF	United Nations Children's Fund
UV	Ultra Violet
WHO	World Health Organisation

Summary

The polyamines putrescine, spermidine and spermine play essential roles in the proliferation and differentiation of most eukaryotic cells. Inhibition of the polyamine pathway is known to have antitumour and antiparasitic effects and α -difluoromethylornithine (DFMO), a polyamine biosynthesis inhibitor, is clinically used in the treatment of African sleeping sickness caused by *Trypanosoma brucei gambiense*. Ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) are the rate-limiting enzymes in polyamine metabolism. Usually, these enzymes are individually regulated, however, in the malaria parasite, *Plasmodium falciparum*, these enzymes are part of a unique bifunctional PfAdoMetDC/ODC protein. In addition, compared to homologous proteins, this malarial protein contains six unique parasite-specific inserted regions, which can be targeted with novel drugs.

A modified restriction enzyme-mediated inverse PCR method was developed to delete the largest parasite-specific insert (411 bp) from the large *PfAdoMetDC/ODC* gene (4257 bp). The method was compared to existing deletion mutagenesis PCR protocols and was shown to be the most effective method (80% mutagenesis efficiency) as opposed to the 40% positively mutated clones obtained with the overlapping primer method in deleting a >100 bp region. The independent removal of all three the PfAdoMetDC domain parasite-specific inserts and subsequent activity analysis thereof showed that these inserts are essential for the catalytic activities of both the decarboxylase domains. *Plasmodia* conserved secondary structures within these inserts were identified and were also shown to be very important for domain activities, possibly through protein-protein interactions across and within the domains of the bifunctional complex for the efficient regulation of intracellular polyamine levels.

The N-terminally located O1 insert in the PfODC domain is a highly conserved and structurally distinct insert, which is essential for both domain activities. Previous studies showed that the deletion of this insert prevents dimerisation of the PfODC monomers and as a result influences association of PfODC with the PfAdoMetDC domain to form the bifunctional ~330 kDa complex. In addition, immobilisation of the insert via the mutagenesis of flanking Gly residues and the disruption of a single conserved α -helix within the insert severely affected both PfODC and PfAdoMetDC activities. It was thus hypothesised that the helix is involved in protein-protein interactions and the dimerisation of the PfODC domain. Size-exclusion chromatography of the monofunctional PfODC and bifunctional PfAdoMetDC/ODC proteins with disrupted helices resulted in the elution of only the monomeric (~85 kDa) and heterodimeric PfAdoMetDC/ODC (~160 kDa) proteins,

respectively. The mono- and bifunctional wild type and immobile proteins eluted as both dimeric PfODC (~170 kDa) and heterotetrameric (~330 kDa) fractions as a result of intact protein-protein interactions. These results were subsequently exploited in the design and application of a parasite-specific, mechanistically novel, inhibitory peptide specific for this non-homologous insert in the bifunctional protein. A 1000x molar excess of a synthetic peptide, complementary to the α -helix within the O1 insert but opposite in charge, resulted in a ~40% inhibition of the PfODC enzyme. This study thus provides a proof-of-principle for the use of an inhibitory peptide targeting a parasite-specific insert in the dimerisation interface of a uniquely bifunctional malarial protein.